MX9205202A - Composicion farmaceutica que comprende rapamicina - Google Patents

Composicion farmaceutica que comprende rapamicina

Info

Publication number
MX9205202A
MX9205202A MX9205202A MX9205202A MX9205202A MX 9205202 A MX9205202 A MX 9205202A MX 9205202 A MX9205202 A MX 9205202A MX 9205202 A MX9205202 A MX 9205202A MX 9205202 A MX9205202 A MX 9205202A
Authority
MX
Mexico
Prior art keywords
rapamicine
pharmaceutical composition
medicament
composition including
pref
Prior art date
Application number
MX9205202A
Other languages
English (en)
Inventor
Craig Eugene Caufield
John Henry Musser
Surendra Nath Sehgal
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of MX9205202A publication Critical patent/MX9205202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
MX9205202A 1991-09-17 1992-09-11 Composicion farmaceutica que comprende rapamicina MX9205202A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76112091A 1991-09-17 1991-09-17

Publications (1)

Publication Number Publication Date
MX9205202A true MX9205202A (es) 1993-03-01

Family

ID=25061205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205202A MX9205202A (es) 1991-09-17 1992-09-11 Composicion farmaceutica que comprende rapamicina

Country Status (23)

Country Link
US (1) US5286730A (es)
EP (1) EP0533433B1 (es)
JP (1) JP2810599B2 (es)
KR (1) KR100299394B1 (es)
AT (1) ATE151289T1 (es)
AU (1) AU659868B2 (es)
CA (1) CA2078379C (es)
CZ (1) CZ281900B6 (es)
DE (1) DE69218864T2 (es)
DK (1) DK0533433T3 (es)
ES (1) ES2100297T3 (es)
GR (1) GR3023680T3 (es)
HK (1) HK108697A (es)
HU (1) HU211112B (es)
IL (3) IL117640A (es)
MX (1) MX9205202A (es)
NZ (2) NZ328124A (es)
PH (1) PH30270A (es)
SG (1) SG43126A1 (es)
SK (1) SK279521B6 (es)
TW (1) TW212759B (es)
UA (1) UA27742C2 (es)
ZA (1) ZA927010B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
JP2741285B2 (ja) * 1992-05-22 1998-04-15 千寿製薬株式会社 緑内障治療剤
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
ES2270948T3 (es) * 1996-07-30 2007-04-16 Novartis Ag Composiciones farmaceuticas para el tratamiento del rechazo de transplantes, asi como las condiciones autoinmunes o inflamatorias.
WO1998018468A1 (en) * 1996-10-31 1998-05-07 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
DE19844397A1 (de) * 1998-09-28 2000-03-30 Hilti Ag Abrasive Schneidkörper enthaltend Diamantpartikel und Verfahren zur Herstellung der Schneidkörper
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
MXPA03002258A (es) 2000-09-19 2003-06-24 Wyeth Corp Esteres de rapamicina solubles en agua.
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
KR20020050135A (ko) * 2000-12-20 2002-06-26 조명재 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
JP2005501868A (ja) 2001-08-22 2005-01-20 ワイス ラパマイシン２９−エノール
WO2003018574A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
TWI307277B (en) 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
JP2006506353A (ja) * 2002-09-17 2006-02-23 ワイス 経口処方
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AU2004231720A1 (en) * 2003-04-22 2004-11-04 Wyeth Antineoplastic combinations
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP2007511521A (ja) * 2003-11-13 2007-05-10 コンビナトアールエックス インコーポレーティッド 炎症性障害を治療する方法および試薬
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
CN104906087A (zh) 2006-09-13 2015-09-16 万能医药公司 大环内酯化合物及它们的使用方法
TW200829232A (en) * 2006-11-07 2008-07-16 Alcon Mfg Ltd Method of treating asthma, allergic rhinitis, and skin disorders
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
WO2010040064A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2416792A4 (en) 2009-04-10 2012-10-24 Haiyan Qi NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
WO2015056160A1 (en) * 2013-10-14 2015-04-23 Izun Pharmaceuticals Ltd. Methods for treatment of m-tor inhibitor-associated stomatitis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2016094732A1 (en) * 2014-12-10 2016-06-16 Transderm, Inc. METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY
JP2018528236A (ja) 2015-09-24 2018-09-27 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US10456383B2 (en) * 2017-06-01 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted approach in the management of Epidermolysis bullosa
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
KR20210087929A (ko) * 2018-08-30 2021-07-13 케미스트리알엑스. 시롤리무스 함유 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4023264A (en) * 1976-06-21 1977-05-17 Littelfuse, Inc. Method of making miniature plug-in fuses of different fuse ratings
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
WO1992002229A1 (en) * 1990-08-10 1992-02-20 Smithkline Beecham Corporation Immunosuppressive compositions
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
SK279521B6 (sk) 1998-12-02
CZ281900B6 (cs) 1997-03-12
HU9202955D0 (en) 1992-12-28
DK0533433T3 (da) 1997-05-12
IL103189A0 (en) 1993-02-21
PH30270A (en) 1997-02-20
ZA927010B (en) 1994-03-14
CZ278592A3 (en) 1993-04-14
EP0533433A1 (en) 1993-03-24
TW212759B (es) 1993-09-11
SG43126A1 (en) 1997-10-17
DE69218864D1 (de) 1997-05-15
EP0533433B1 (en) 1997-04-09
ES2100297T3 (es) 1997-06-16
JPH05194529A (ja) 1993-08-03
IL117640A0 (en) 1996-07-23
HU211112B (en) 1995-10-30
UA27742C2 (uk) 2000-10-16
IL103189A (en) 1996-08-04
JP2810599B2 (ja) 1998-10-15
AU659868B2 (en) 1995-06-01
CA2078379A1 (en) 1993-03-18
IL117640A (en) 1999-08-17
ATE151289T1 (de) 1997-04-15
KR100299394B1 (ko) 2001-10-22
DE69218864T2 (de) 1997-07-17
SK278592A3 (en) 1995-03-08
NZ244340A (en) 1999-06-29
HUT64846A (en) 1994-03-28
US5286730A (en) 1994-02-15
AU2450792A (en) 1993-03-18
CA2078379C (en) 2003-07-29
NZ328124A (en) 2000-01-28
GR3023680T3 (en) 1997-09-30
HK108697A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
MX9205202A (es) Composicion farmaceutica que comprende rapamicina
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
PT758900E (pt) Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
EP0687175A4 (en) METHOD OF TREATING EMOTIONAL OR MENTAL ILLNESS, AND EMOTIONAL OR MENTAL ILLNESS CONCURRENT TO CRISIS
MY106242A (en) Pharmaceutical composition for the prevention of sexually transmitted diseases.
ES2194210T3 (es) Forma de dosificacion para suministrar una dosis ascendente de farmaco.
ES2167609T3 (es) Formulaciones de quinolona inyectables.
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE210429T1 (de) Therapie mittels gleichförmiger arzneistoffverabreichung
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
ES2196167T3 (es) Composicion farmaceutica que contiene propionato de 3-(2,2,2-trimetilhidrazinio) y gamma-butirobetaina para el tratamiento de enfermedades cardiovasculares.
CO5031291A1 (es) Composicion farmaceutica
JPS6483020A (en) Medicinal composition for preventing or treating aids
NO990450L (no) Behandling av sinnslidelser
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
SE9504267D0 (sv) New therapeutic use
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
SE9602262D0 (sv) New use of derivatives of cystine
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
AU4250697A (en) Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
NO990947D0 (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: BAYER CROPSCIENCE AG.*

MM Annulment or lapse due to non-payment of fees